These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9648627)

  • 1. Effects of receptor blockade on metabolism and renal actions of vasopressin in conscious dogs.
    Grove L; Christensen P; Bie P
    Acta Physiol Scand; 1998 May; 163(1):93-101. PubMed ID: 9648627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
    Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
    J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.
    Oshikawa S; Tanoue A; Koshimizu TA; Kitagawa Y; Tsujimoto G
    Mol Pharmacol; 2004 Mar; 65(3):623-9. PubMed ID: 14978240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
    Oldziej S; Ciarkowski J; Liwo A; Shenderovich MD; Grzonka Z
    J Recept Signal Transduct Res; 1995; 15(1-4):703-13. PubMed ID: 8903974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of vasopressin receptor antagonist OPC-31260 on experimental brain oedema induced by global cerebral ischaemia.
    Molnár AH; Varga C; Berkó A; Rojik I; Párducz A; László F; László FA
    Acta Neurochir (Wien); 2008 Mar; 150(3):265-71. PubMed ID: 18288441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.
    Naitoh M; Suzuki H; Murakami M; Matsumoto A; Arakawa K; Ichihara A; Nakamoto H; Oka K; Yamamura Y; Saruta T
    Am J Physiol; 1994 Dec; 267(6 Pt 2):H2245-54. PubMed ID: 7810724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of AVP-V2 receptor stimulation on local GFR in the rat kidney.
    Roald AB; Tenstad O; Aukland K
    Acta Physiol Scand; 2000 Feb; 168(2):351-9. PubMed ID: 10712572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
    Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M; Poo JL; Jiménez W; Bordas N; Leivas A; Morales-Ruiz M; Muñoz RM; Pérez M; Arroyo V; Rivera F; Rodés J
    J Pharmacol Exp Ther; 1999 Apr; 289(1):194-201. PubMed ID: 10087004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the water diuretic activity of kappa receptor agonists and a vasopressin receptor antagonist in dogs.
    Brooks DP; Valente M; Petrone G; Depalma PD; Sbacchi M; Clarke GD
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1176-83. PubMed ID: 9067301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of vasopressin natriuresis in the dog: role of vasopressin receptors and prostaglandins.
    Kompanowska-Jezierska E; Emmeluth C; Grove L; Christensen P; Sadowski J; Bie P
    Am J Physiol; 1998 Jun; 274(6):R1619-25. PubMed ID: 9608016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term clinical trial of 1-(1-[4-(3-acetylaminopropoxy)-benzoyl]-4-piperidyl)-3, 4-dihydro-2(1H)-quinolinone in patients with diabetic nephropathy. Possible effectiveness of the specific vasopressin V1 receptor antagonist for reducing albuminuria in patients with non-insulin dependent diabetes mellitus.
    Nishikawa T; Omura M; Iizuka T; Saito I; Yoshida S
    Arzneimittelforschung; 1996 Sep; 46(9):875-8. PubMed ID: 8876935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
    Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blocking effects of OPC-21268 and OPC-31260 (vasopressin V1- and V2-receptor antagonists) on vasopressin-induced constrictions in isolated, perfused dog femoral arteries.
    Chiba S; Tsukada M
    Jpn J Pharmacol; 1992 May; 59(1):133-5. PubMed ID: 1324373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
    Nakamura T; Sakamaki T; Kurashina T; Hoshino J; Sato K; Ono Z; Murata K
    Life Sci; 1994; 55(4):PL67-72. PubMed ID: 8028441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin receptor subtypes on mesenteric and cremasteric arterioles in rat.
    Ishiguro S; Iwasaki T; Miyamoto A; Mori T; Nishio A
    Eur J Pharmacol; 2000 Jul; 400(1):121-5. PubMed ID: 10913593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organic osmolytes in rat renal inner medulla are modulated by vasopressin V1 and/or V2 antagonists.
    Nakanishi T; Yamauchi A; Nakahama H; Yamamura Y; Yamada Y; Orita Y; Fujiwara Y; Uyeda N; Takamitsu Y; Sugita M
    Am J Physiol; 1994 Jul; 267(1 Pt 2):F146-52. PubMed ID: 8048555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arg8]vasopressin-induced responses of the human isolated coronary artery: effects of non-peptide receptor antagonists.
    Bax WA; Van der Graaf PH; Stam WB; Bos E; Nisato D; Saxena PR
    Eur J Pharmacol; 1995 Oct; 285(2):199-202. PubMed ID: 8566139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.